Qualigen Therapeutics Overview
Latest ROE for Qualigen Therapeutics: -448.16% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-448.16%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for QLGN is -448.16%. That is below the Healthcare sector average of 22.01%. Investors often review this figure alongside Qualigen Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, QLGN currently prints -448.16% for ROE, while the sector average sits near 22.01%. That is roughly 2136.2% below the sector mean. Large gaps often invite a closer look at Qualigen Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Qualigen Therapeutics converts resources into returns. At -448.16%, QLGN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting QLGN's ROE (-448.16%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Qualigen Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
